Catalyst Wire Dossier Catalyst Wire Dossier

CHF5993 HFA-134a pMDI

CHF5993 · Chiesi Farmaceutici S.p.A.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CHF5993 HFA-134a pMDI, covering 2026-04-14 to 2026-04-14. Get the full timeline:

Most recent: Clinical Trial Update: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). [Phase 3]

See pricing